Keyword: Sandoz

The Sandoz manufacturing network will be further 'optimized' as Novartis turns Sandoz into an autonomous unit in the next 18 months.

Thanks to groundwork laid by the feds, UnitedHealthcare is suing dozens of generics companies for alleged price fixing—and it wants its money back.

Novartis' Sandoz picked three finalists in its crowdsourced digital healthcare challenge, who'll now move to a final pitch at South by Southwest.

Adamis' partner Sandoz is launching the prefilled syringe at a 16.5% discount to Mylan’s authorized generic EpiPen and Teva’s generic version.

Following an EpiPen generic launch by Teva, Novartis' Sandoz has released its launch plans for epinephrine alternative Symjepi.

Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie.

A U.S. biotech that bought nearly 30 generic drugs from Sandoz in January says it has plans to build its first manufacturing facility in China.

Just one day after Novartis laid out plans for its Alcon spinoff, it found itself fending off a rumor that it also intends to wave goodbye to Sandoz.

Months after world regulators first discovered impurities in the ingredient of a Chinese ingredient maker, tainted drugs continue to show up in the U.S. supply.

Coherus won an FDA nod for its biosimilar to Amgen's Neulasta, heating up the market share fight—and touching off predictions of price competition.